Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease.
Yusuke YoshimuraMasayuki YamanouchiHiroki MizunoDaisuke IkumaRyo KoizumiShigekazu KuriharaYuki ObaTatsuya SuwabeYuichiro SawadaHisashi KamidoHisashi SugimotoMasato MizutaAkinari SekineEiko HasegawaYoshifumi UbaraNaoki SawaPublished in: Annals of the rheumatic diseases (2024)
and fewer discontinuations due to ineffectiveness. IL-6is were more efficacious as monotherapy compared with the other bDMARDs.